株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のインフルエンザ市場

The Global Influenza Market

発行 BCC Research 商品コード 99390
出版日 ページ情報 英文 196 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界のインフルエンザ市場 The Global Influenza Market
出版日: 2013年11月12日 ページ情報: 英文 196 Pages
概要

当レポートでは、世界におけるインフルエンザ向けワクチン・治療・診断市場の評価を行い、疾患の概要や、世界市場の今後5年間の予測、重要な課題、動向、市場要因、各国政府の対応策、主要企業のプロファイルなどを提供しており、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 産業概要

  • 定義
  • 市場の歴史
    • エピデミックとパンデミック
    • ウイルスの突然変異
    • インフルエンザの種類
    • 世界におけるインフルエンザの活動
  • WHO(世界保健機器)およびCDC(連邦防疫センター)のインフルエンザへの反応
  • 米国におけるウイルスの監視
  • 推奨ワクチン
  • インフルエンザワクチンの開発
    • ユニバーサルワクチン
  • 世界の人口統計とインフルエンザの発症/インフルエンザによる死亡

第4章 市場に影響する課題

  • H1N1(新型インフルエンザ)の発生:2009年
    • 迅速診断
  • 鳥インフルエンザ
    • 米国政府の介入
    • 監視
  • 国際的なインフルエンザワクチンの備蓄指令
    • 予防接種
  • 抗ウイルス耐性
  • 米国保健福祉省(HHS)の関連技術に関する契約
  • 計画の具体化に失敗した市場
  • メディア報道と予防接種
  • エピデミック/パンデミックの恐れ
  • 世界各国での感染への事前準備・計画
  • 抗ウイルス耐性

第5章 特許分析

  • 概要
  • 特許番号別のインフルエンザ特許

第6章 インフルエンザワクチン

  • 概要
  • 現在のワクチン(全8種)
  • FDAによる、季節性インフルエンザ向けワクチンの認可
  • ワクチンの開発
    • 各社の動向(全22社)
    • 最近の産業ニュース
  • 世界のインフルエンザワクチン市場
  • 地域市場のサマリー
  • 競合分析

第7章 インフルエンザの治療法

  • 概要
  • 現在の治療法
  • 季節性インフルエンザに対する、推奨される抗ウイルス剤療法
  • ジェネリック医薬品の入手可能性
  • インフルエンザ向け生物製剤の開発(全12件)
  • 世界のインフルエンザ治療法の市場
    • 地域市場のサマリー(米国・欧州)
  • 競合企業の分析

第8章 インフルエンザワクチン・治療薬市場の分析

  • 治験の進行状況

第9章 インフルエンザの診断

  • 概要
    • 検査方法の説明
    • 製品の説明
      • 従来型の臨床検査
      • 迅速試験
    • ラボラトリーサービス
    • 近年の業界動向
  • 市場分析
    • 地域市場のサマリー
  • 競合企業の分析

第10章 インフルエンザ市場のサマリー

  • 総市場の分析
    • 地域市場のサマリー
  • インフルエンザ市場の動向:概況
    • 市場参入企業

第11章 企業プロファイル

  • 主な企業買収情報
  • ABBOTT LABORATORIES
  • ALERE INC.
  • ASTRAZENECA/MEDIMMUNE
  • BECTON DICKINSON AND COMPANY
  • CSL LIMITED
  • GLAXOSMITHKLINE PLC
  • 三菱田辺製薬
  • NOVARTIS AG
  • QUIDEL CORP.
  • ROCHE LTD.
  • SANOFI/SANOFI PASTEUR

第12章 付録

  • 付録I:メーカーと開発企業
  • 付録II:本文中で言及した大学・研究機関
  • 付録III:用語集
  • 付録IV:略語集

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM049C

The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.

This report provides:

  • An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 and 2018.
  • Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
  • Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
  • Comprehensive company profiles of major players.

STUDY GOALS AND OBJECTIVES

This BCC Research report, The Global Influenza Market is an update to the latest edition of the BCC Research report published in 2009. This report provides an overview of products currently in the marketplace and a detailed analysis of market position and competitive environments. The study includes information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers. There is a special emphasis on U.S. and European markets.

REASONS FOR DOING THE STUDY

Annually, up to a half-million people die of influenza and, with the threat of a pandemic in any given year, government agencies and disease prevention organizations are devoted to gaining control of the situation. The 2009 pandemic generated attention to surveillance measures, pandemic preparedness, vaccine production and antiviral control. It also revealed issues with laboratory capacity and the benefits of rapid testing in a pandemic situation.

Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next five years will continue to display support and funding for many research and development (R&D) programs, product development, and pandemic prevention and/or control by worldwide governments, organizations, and health professionals.

SCOPE OF REPORT

This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

ANALYST CREDENTIALS

Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over-the-counter pharmaceuticals, medical devices and emerging healthcare technologies. Ms. Elder has over 20 years of experience in the healthcare industry, specializing in market research for the past 15 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • INTENDED AUDIENCE
  • RELATED BCC RESEARCH STUDIES
  • ANALYST CREDENTIALS
  • BCC RESEARCH ON-LINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY
  • SUMMARY TABLE: GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2018 ($ MILLIONS)

CHAPTER 3 - INDUSTRY OVERVIEW

  • OVERVIEW
  • HISTORY OF THE MARKET
    • EPIDEMICS/PANDEMICS
      • Spanish Influenza 1918-1919
      • Hong Kong Influenza 1968
      • Asian Influenza 1957
      • Swine Flu 1976
      • Russian Influenza 1977
      • Avian Flu 1961, 1997, 2003-2009/2010 (Sporadic)
      • Novel Influenza H1N1 2009
        • TABLE 1: DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO REGION
      • Novel Influenza H7N9
        • TABLE 2: CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY MONTH, AS OF AUGUST 2013
        • TABLE 3: NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST 2013
    • VIRUS MUTATIONS
    • TYPES OF INFLUENZA
      • Influenza Type A
      • Influenza A H5
      • Influenza A H7
      • Influenza A H9
      • Influenza A H1
      • Influenza A H10
      • Influenza Type B
      • Influenza Type C
    • WORLD ACTIVITY OF INFLUENZA VIRUSES
      • TABLE 4: WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE
    • THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE
      • WORLD HEALTH ORGANIZATION
      • CENTERS FOR DISEASE CONTROL AND PREVENTION
    • U.S. VIRAL SURVEILLANCE
      • TABLE 5: VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)
      • FIGURE 1: VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)
    • FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE AND VACCINE COMPOSITION
      • TABLE 6: INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS, 2003-2014
    • VACCINE RECOMMENDATIONS
      • TABLE 7: THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)
      • TABLE 8: CDC INFLUENZA VACCINE RECOMMENDATIONS
      • FIGURE 2: RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, U.S., 2013-2014 INFLUENZA SEASON
    • UNIVERSAL VACCINE
  • POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY
    • GLOBAL DEMOGRAPHICS
      • TABLE 9: GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 3: GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
      • TABLE 10: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
      • FIGURE 4: GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)
    • GLOBAL LIFE EXPECTANCY
      • TABLE 11: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
      • FIGURE 5: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
    • INFLUENZA INCIDENCE AND MORTALITY
      • TABLE 12: WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND POPULATION
      • TABLE 13: U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION
      • TABLE 14: IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP APRIL 2009-APRIL 2010

CHAPTER 4 - ISSUES AFFECTING THE MARKET

  • H1N1 OUTBREAK 2009 (SWINE FLU)
    • RAPID DIAGNOSTICS
      • Pandemic Testing
      • Seasonal Influenza Tests
  • AVIAN FLU
    • U.S. GOVERNMENT INTERVENTION
      • TABLE 15: COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS
    • AVIAN FLU SURVEILLANCE
      • TABLE 16: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)
      • FIGURE 6: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)
    • Avian Flu (H5N1) Outbreaks in Animals
      • TABLE 17: CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO AUGUST 19, 2013 (NUMBER)
      • FIGURE 7: CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER)
    • The WHO and Containment for Pandemic Influenza
      • TABLE 18: APPROVED WHO INFLUENZA CENTERS BY REGION
      • FIGURE 8: NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)
  • INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS
    • PRE-PANDEMIC VACCINATION
      • TABLE 19: TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS)
    • Biomedical Advanced Research and Development Authority (BARDA)
  • ANTIVIRAL RESISTANCE
    • RECREATED VIRUSES
    • HHS CONTRACTS FOR RELATED TECHNOLOGIES
      • TABLE 20: HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF RECOMBINANT INFLUENZA VACCINE
  • MARKET FAILURE TO MATERIALIZE
    • MEDIA COVERAGE AND VACCINATIONS
    • EPIDEMIC/PANDEMIC THREAT
      • TABLE 21: ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)
    • PANDEMIC PREPAREDNESS PLANS
      • TABLE 22: ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN
    • THE UNITED STATES
    • JAPAN
      • TABLE 23: OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS
    • CHINA
      • TABLE 24: CHINA INFLUENZA PANDEMIC WARNING LEVELS
    • BRAZIL
      • TABLE 25: BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION
    • UNITED KINGDOM
  • WORLD INFLUENZA IMPACT
    • IMPACT OF SEASONAL FLU ON THE U.S. ECONOMY
      • TABLE 26: NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET AL., 2007
    • HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC
      • TABLE 27: ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES
      • FIGURE 9: ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES (NUMBER)
    • ANTIVIRAL RESISTANCE

CHAPTER 5 - PATENT ANALYSIS

  • OVERVIEW
    • INFLUENZA PATENTS BY PATENT NUMBER
      • TABLE 28: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)
      • FIGURE 10: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)
      • TABLE 29: RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER
      • TABLE 30: NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR
  • BRISTOL-MYERS SQUIBB
  • CRUCELL HOLLAND
  • MEDIMMUNE
  • NEW YORK UNIVERSITY
  • NOVARTIS
  • NOVAVAX
  • UNIVERSITY OF PITTSBURGH
  • WISCONSIN ALUMNI RESEARCH FOUNDATION
  • YEDA RESEARCH AND DEVELOPMENT

CHAPTER 6 - INFLUENZA VACCINES

  • OVERVIEW
    • HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S.
      • TABLE 31: VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014 INFLUENZA YEAR
  • CURRENT VACCINES
    • BAXTER INTERNATIONAL
    • CSL BIOTHERAPIES
    • GLAXOSMITHKLINE
    • MEDIMMUNE
    • NOVARTIS
    • PROTEIN SCIENCES CORP.
    • SANOFI PASTEUR
    • SOLVAY PHARMACEUTICALS
      • TABLE 32: EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS
    • SEASONAL 2008-2009 VACCINE APPROVALS BY FDA
      • TABLE 33: SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014 INFLUENZA SEASON, BASED ON ADULT DOSAGE
    • RECENT PRE-PANDEMIC AND PANDEMIC APPROVALS
  • VACCINE DEVELOPMENTS
    • ALPHAVAX
    • ANTIGEN EXPRESS
    • BIONDVAX PHARMACEUTICALS
    • CRUCELL
    • CURELAB
    • GENEREX BIOTECHNOLOGY
    • IBIO, INC.
    • INOVIO PHARMACEUTICALS
    • MEDICAGO
    • MEDIMMUNE
    • NANOBIO CORP.
    • NANOTHERAPEUTICS, INC.
    • NANOVIRICIDES, INC.
    • NEXBIO, INC.
    • NOVARTIS VACCINES
    • NOVAVAX, INC.
    • PAXVAX CORP.
    • PROTEIN SCIENCES CORP.
    • SANOFI PASTEUR
    • VAXART, INC.
    • VAXIN, INC.
    • VAXINNATE
      • TABLE 34: RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS
      • FIGURE 11: NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY PROGRESS
  • RECENT INDUSTRY NEWS
    • THE GLOBAL INFLUENZA VACCINE MARKET
      • TABLE 35: GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
      • FIGURE 12: GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • SEASONAL VS. PANDEMIC SALES
      • FIGURE 13: GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2013 ($ MILLIONS)
    • REGIONAL MARKET SUMMARY
      • TABLE 36: GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 ($ MILLIONS)
      • FIGURE 14: GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 ($ MILLIONS)
      • FIGURE 15: DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION, 2013 (%)
    • THE U.S. INFLUENZA VACCINE MARKET
      • TABLE 37: U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007-2018 ($ MILLIONS)
      • FIGURE 16: U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
      • TABLE 38: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON, 2005-2013
      • FIGURE 17: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013
      • TABLE 39: UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION)
      • FIGURE 18: SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (%)
    • THE EUROPEAN INFLUENZA VACCINE MARKET
      • TABLE 40: EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
      • FIGURE 19: EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • COMPETITOR ANALYSIS
      • TABLE 41: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010-2013 (%)
      • FIGURE 20: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010 (%)
      • FIGURE 21: LEADING PARTICIPANTS' SHARE OF INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)
      • FIGURE 22: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2012 (%)
      • FIGURE 23: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2013 (%)

CHAPTER 7 - INFLUENZA THERAPIES

  • OVERVIEW
  • CURRENT THERAPIES
    • GLAXOSMITHKLINE
    • ROCHE
    • OTHERS
      • TABLE 42: MARKETED THERAPIES, THROUGH 2013
    • SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS
      • TABLE 43: RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S.
    • GENERIC AVAILABILITY
      • TABLE 44: GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS
  • INFLUENZA BIOLOGICAL DEVELOPMENTS
    • ADAMAS PHARMACEUTICALS
    • AMARILLO BIOSCIENCES, INC.
    • BIOCRYST PHARMACEUTICALS
    • BIOTA HOLDINGS
    • CRUCELL
    • FUNCTIONAL GENETICS, INC.
    • GLAXOSMITHKLINE
    • HEMISPHERX BIOPHARMA
    • ROMARK LABORATORIES
    • SAREPTA THERAPEUTICS
    • THERACLONE SCIENCES
    • TOYAMA CHEMICAL
      • TABLE 45: RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS
    • THE GLOBAL INFLUENZA THERAPEUTICS MARKET
      • TABLE 46: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
      • FIGURE 24: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • REGIONAL MARKET SUMMARY
      • TABLE 47: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 25: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, 2010-2018 ($ MILLIONS)
      • FIGURE 26: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY REGION, 2013 (%)
    • Influenza Therapeutics Market in The U.S.
      • TABLE 48: U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
      • FIGURE 27: U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • Influenza Therapeutics Market In Europe
      • TABLE 49: EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
      • FIGURE 28: EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • COMPETITOR ANALYSIS
      • TABLE 50: LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010-2013 (%)
      • FIGURE 29: LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010 (%)
      • FIGURE 30: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)
      • FIGURE 31: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2012 (%)
      • FIGURE 32: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2013 (%)

CHAPTER 8 - INFLUENZA VACCINE/THERAPEUTICS MARKET ANALYSIS

  • TABLE 51: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, THROUGH 2018 ($ MILLIONS)
  • FIGURE 33: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2010-2018 ($ MILLIONS)
  • FIGURE 34: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES SALES BY REGION, 2013 (%)
  • TABLE 52: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
  • FIGURE 35: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2010-2018 ($ MILLIONS)
  • FIGURE 36: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2013 (%)
  • CLINICAL TRIALS
    • TABLE 53: CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS
    • FIGURE 37: CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS

CHAPTER 9 - INFLUENZA DIAGNOSTICS

  • OVERVIEW
    • TABLE 54: INFLUENZA DIAGNOSTIC TABLE
  • TEST DESCRIPTIONS2
    • Viral Culture
    • Rapid Influenza Diagnostic Tests
      • TABLE 55: CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS HIGH (%)
      • TABLE 56: CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS LOW (%)
    • Serologic Testing
  • PRODUCT DESCRIPTION
    • Conventional Laboratory Tests
      • Applied Biosystems
      • Qiagen, Inc.
    • Rapid Testing
      • 3M and Response Biomedical Corp.
      • Alere
      • Becton Dickinson
      • BTNX, Inc.
      • Cepheid
      • Hologic, Inc.
      • Luminex Corp.
      • Meridian Biosciences, Inc.
      • OraSure Technologies
      • Quidel Corp.
      • Remel, Inc. (Thermo Scientific)
      • SA Scientific, Ltd.
      • Sekisui Diagnostics
        • TABLE 57: SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013
        • TABLE 58: SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE ($)
    • LABORATORY SERVICES
      • Associated Regional University Pathologists (ARUP) Laboratories
      • Bio-Reference Laboratories, Inc.
      • Laboratory Corp. of America
      • Pathology Associates Medical Laboratories
      • Quest Diagnostics
        • TABLE 59: PROVIDERS OF TEST SERVICES
    • RECENT INDUSTRY NEWS
  • MARKET ANALYSIS
    • TABLE 60: REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
    • FIGURE 38: REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2010-2018 ($ MILLIONS)
  • REGIONAL MARKET SUMMARY
    • TABLE 61: GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • FIGURE 39: GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 40: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2013 (%)
    • TABLE 62: NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*
    • FIGURE 41: NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*
  • COMPETITOR ANALYSIS
    • TABLE 63: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010-2013 ($)
    • FIGURE 42: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010 (%)
    • FIGURE 43: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2011 (%)
    • FIGURE 44: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2012 (%)
    • FIGURE 45: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2013 (%)

CHAPTER 10 - INFLUENZA MARKET SUMMARY

  • TOTAL MARKET ANALYSIS
    • TABLE 64: GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2018 ($ MILLIONS)
    • FIGURE 46: GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, 2010-2018 ($ MILLIONS)
    • FIGURE 47: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2013 (%)
  • REGIONAL MARKET SUMMARY
    • TABLE 65: GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 ($ MILLIONS)
    • FIGURE 48: GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 49: DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%)
  • OVERVIEW OF INFLUENZA MARKET TRENDS
    • TABLE 66: INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS
    • TABLE 67: INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS
    • TABLE 68: INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS
  • INDUSTRY PARTICIPANTS
    • TABLE 69: MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE

CHAPTER 11 - COMPANY PROFILES

  • SIGNIFICANT COMPANY ACQUISITIONS
    • ABBOTT LABORATORIES
      • TABLE 70: ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 50: ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • ALERE INC.
      • TABLE 71: ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 51: ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • ASTRAZENECA/MEDIMMUNE
      • TABLE 72: ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 52: ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • BECTON DICKINSON AND COMPANY
      • TABLE 73: BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 53: BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • CSL LIMITED
      • TABLE 74: CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS)
      • FIGURE 54: CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS)
    • GLAXOSMITHKLINE PLC
      • TABLE 75: GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 55: GLAXOSMITHKLINE'S COMPANY REVENUES 2009-2012 ($ MILLIONS)
    • MITSUBISHI TANABE PHARMA CORP.
      • TABLE 76: MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 56: MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • NOVARTIS AG
      • TABLE 77: NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 57: NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • QUIDEL CORP.
      • TABLE 78: QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 58: QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • ROCHE LTD.
      • TABLE 79: ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 59: ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS)
    • SANOFI/SANOFI PASTEUR
      • TABLE 80: SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
      • FIGURE 60: SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)

CHAPTER 12 - APPENDICES

  • APPENDIX I
    • MANUFACTURERS AND DEVELOPERS
  • APPENDIX II
    • MENTIONED UNIVERSITIES AND SCHOOLS
  • APPENDIX III
    • GLOSSARY OF TERMS3
  • APPENDIX IV
    • LIST OF ACRONYMS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO REGION
    • TABLE 2: CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY MONTH, AS OF AUGUST 2013
    • TABLE 3: NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST 2013
    • TABLE 4: WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE
    • TABLE 5: VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)
    • TABLE 6: INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS, 2003-2014
    • TABLE 7: THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)
    • TABLE 8: CDC INFLUENZA VACCINE RECOMMENDATIONS
    • TABLE 9: GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
    • TABLE 10: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
    • TABLE 11: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
    • TABLE 12: WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND POPULATION
    • TABLE 13: U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION
    • TABLE 14: IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP APRIL 2009-APRIL 2010
    • TABLE 15: COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS
    • TABLE 16: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)
    • TABLE 17: CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO AUGUST 19, 2013 (NUMBER)
    • TABLE 18: APPROVED WHO INFLUENZA CENTERS BY REGION
    • TABLE 19: TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS)
    • TABLE 20: HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF RECOMBINANT INFLUENZA VACCINE
    • TABLE 21: ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)
    • TABLE 22: ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN
    • TABLE 23: OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS
    • TABLE 24: CHINA INFLUENZA PANDEMIC WARNING LEVELS
    • TABLE 25: BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION
    • TABLE 26: NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET AL., 2007
    • TABLE 27: ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES
    • TABLE 28: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)
    • TABLE 29: RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER
    • TABLE 30: NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR
    • TABLE 31: VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014 INFLUENZA YEAR
    • TABLE 32: EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS
    • TABLE 33: SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014 INFLUENZA SEASON, BASED ON ADULT DOSAGE
    • TABLE 34: RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS
    • TABLE 35: GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
    • TABLE 36: GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 ($ MILLIONS)
    • TABLE 37: U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007-2018 ($ MILLIONS)
    • TABLE 38: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON, 2005-2013
    • TABLE 39: UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION)
    • TABLE 40: EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010-2013 (%)
    • TABLE 42: MARKETED THERAPIES, THROUGH 2013
    • TABLE 43: RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S.
    • TABLE 44: GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS
    • TABLE 45: RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS
    • TABLE 46: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010-2013 (%)
    • TABLE 51: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 52: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS
    • TABLE 54: INFLUENZA DIAGNOSTIC TABLE
    • TABLE 55: CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS HIGH (%)
    • TABLE 56: CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS LOW (%)
    • TABLE 57: SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013
    • TABLE 58: SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE ($)
    • TABLE 59: PROVIDERS OF TEST SERVICES
    • TABLE 60: REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 61: GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 62: NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*
    • TABLE 63: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010-2013 ($)
    • TABLE 64: GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2018 ($ MILLIONS)
    • TABLE 65: GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 66: INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS
    • TABLE 67: INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS
    • TABLE 68: INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS
    • TABLE 69: MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE
    • TABLE 70: ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 71: ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 72: ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 73: BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 74: CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS)
    • TABLE 75: GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 76: MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 77: NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 78: QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 79: ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS)
    • TABLE 80: SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2018 ($ MILLIONS)
    • FIGURE 1: VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)
    • FIGURE 2: RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, U.S., 2013-2014 INFLUENZA SEASON
    • FIGURE 3: GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
    • FIGURE 4: GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)
    • FIGURE 5: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
    • FIGURE 6: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)
    • FIGURE 7: CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER)
    • FIGURE 8: NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)
    • FIGURE 9: ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES (NUMBER)
    • FIGURE 10: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)
    • FIGURE 11: NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY PROGRESS
    • FIGURE 12: GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 13: GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2013 ($ MILLIONS)
    • FIGURE 14: GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 ($ MILLIONS)
    • FIGURE 15: DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION, 2013 (%)
    • FIGURE 16: U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 17: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013
    • FIGURE 18: SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (%)
    • FIGURE 19: EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 20: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010 (%)
    • FIGURE 21: LEADING PARTICIPANTS' SHARE OF INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)
    • FIGURE 22: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2012 (%)
    • FIGURE 23: LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2013 (%)
    • FIGURE 24: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 25: GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 26: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY REGION, 2013 (%)
    • FIGURE 27: U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 28: EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 ($ MILLIONS)
    • FIGURE 29: LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010 (%)
    • FIGURE 30: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)
    • FIGURE 31: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2012 (%)
    • FIGURE 32: LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2013 (%)
    • FIGURE 33: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 34: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES SALES BY REGION, 2013 (%)
    • FIGURE 35: REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2010-2018 ($ MILLIONS)
    • FIGURE 36: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2013 (%)
    • FIGURE 37: CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS
    • FIGURE 38: REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2010-2018 ($ MILLIONS)
    • FIGURE 39: GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 40: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2013 (%)
    • FIGURE 41: NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*
    • FIGURE 42: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010 (%)
    • FIGURE 43: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2011 (%)
    • FIGURE 44: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2012 (%)
    • FIGURE 45: LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2013 (%)
    • FIGURE 46: GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, 2010-2018 ($ MILLIONS)
    • FIGURE 47: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2013 (%)
    • FIGURE 48: GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 ($ MILLIONS)
    • FIGURE 49: DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%)
    • FIGURE 50: ABBOTT'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 51: ALERE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 52: ASTRAZENECA'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 53: BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 54: CSL LIMITED'S COMPANY REVENUES, 2009-2013* ($ MILLIONS)
    • FIGURE 55: GLAXOSMITHKLINE'S COMPANY REVENUES 2009-2012 ($ MILLIONS)
    • FIGURE 56: MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 57: NOVARTIS' COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 58: QUIDEL'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 59: ROCHE GROUP'S REVENUES, 2009-2012 ($ MILLIONS)
    • FIGURE 60: SANOFI'S COMPANY REVENUES, 2009-2012 ($ MILLIONS)
Back to Top